Non-exclusive Drug Discount Agreement for Fluorouracil (ATC L01BC02 / D11AF05)
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Fluorouracil (ATC-Code nach WHO: L01BC02; amtlicher ATC-Code: D11AF05)
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
No minimum purchase quantities; actual demand is uncertain and entirely dependent on prescribing and dispensing pattern...
The buyer may end the Open-House procedure if exclusive agreements are signed, which typically occur 8-12 months after...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Jul 31, 2027
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Jul 2027
- Conclusion of non-exclusive discount agreements for Fluorouracil medicinal products
- Open-House model – any interested pharmaceutical company that meets the conditions can participate
Show full summary
This is a non-exclusive drug discount agreement (Rabattvereinbarung) under § 130a Abs. 8 SGB V for the active ingredient Fluorouracil, using an Open-House model. The AOK PLUS health insurance fund invites all interested pharmaceutical companies to participate without negotiation or exclusivity. The agreement runs until 31 July 2027. No minimum purchase quantities are guaranteed. The procedure is published for transparency purposes and is not a classic public procurement. All communication and document exchange occurs via the DTVP portal. Strict confidentiality applies. First submission deadline for contracts starting 1 August 2025 is 23 June 2025; subsequent deadlines are specified in a separate schedule.
Risks
No minimum purchase quantities; actual demand is uncertain and entirely dependent on prescribing and dispensing pattern...
The buyer may end the Open-House procedure if exclusive agreements are signed, which typically occur 8-12 months after...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical manufacturer as defined in § 4(18) AMG with respect to the offered products
Eligibility
- Must submit a self-declaration on absence of exclusion grounds (§§ 123, 124 GWB)
Administrative
- Must submit a self-declaration regarding Russia sanctions (EU Regulation 833/2014)
Requirements may be incomplete.
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-exclusive Drug Discount Agreement for Fluorouracil (ATC L01BC02 / D11AF05)
Non-exclusive discount agreement for fluorouracil-containing medicinal products. Single lot open to all qualified pharmaceutical manufacturers. No guaranteed volumes or exclusivity.
Location
Duration
Category
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Fluorouracil (ATC-Code nach WHO: L01BC02; amtlicher ATC-Code: D11AF05)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 29 May 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 348750-2025
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
No minimum purchase quantities; actual demand is uncertain and entirely dependent on prescribing and dispensing pattern...
The buyer may end the Open-House procedure if exclusive agreements are signed, which typically occur 8-12 months after...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications